Home Cart Sign in  
Chemical Structure| 1204317-86-1 Chemical Structure| 1204317-86-1

Structure of Edasalonexent
CAS No.: 1204317-86-1

Chemical Structure| 1204317-86-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Edasalonexent is an orally bioavailable NF-κB inhibitor.

Synonyms: CAT-1004

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Edasalonexent

CAS No. :1204317-86-1
Formula : C31H42N2O3
M.W : 490.68
SMILES Code : O=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O
Synonyms :
CAT-1004
MDL No. :MFCD30533433

Safety of Edasalonexent

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Edasalonexent

pyroptosis

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02439216 Muscular Dystrophy, Duchenne Phase 1 Phase 2 Active, not recruiting August 2019 United States, California ... More >> Los Angeles, California, United States, 90095 United States, Florida Gainesville, Florida, United States, 32610 Orlando, Florida, United States, 32827 United States, Oregon Portland, Oregon, United States, 97239 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT03703882 Muscular Dystrophy, Duchenne Phase 3 Recruiting June 2020 United States, Arkansas ... More >> Arkansas Children's Hospital Recruiting Little Rock, Arkansas, United States, 72202 Contact: Vikki A Stefans, MD          Principal Investigator: Vikki A Stefans, MD          United States, Georgia Rare Disease Research, LLC Recruiting Atlanta, Georgia, United States, 30318 Contact: Tu Tran, BS          Principal Investigator: Han Phan, MD          United States, Maryland Kennedy Krieger Institute Recruiting Baltimore, Maryland, United States, 21205 Contact: Genila Bibat, MD          Principal Investigator: Katherine R Wagner, MD, PhD          United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Amy Hurst, CCRC          Principal Investigator: Erin Neil, DO          United States, Oregon Shriners Hospitals for Children Recruiting Portland, Oregon, United States, 97239 Contact: Paige Lemhouse, BS          Principal Investigator: Erika Finanger, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.19mL

2.04mL

1.02mL

20.38mL

4.08mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories